Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Why is this Company combining Artificial Intelligence and Psychedelics to address Mental Afflictions

(Click image to play video) Did you know that in Canada, it is estimated that by the age of 40, half of the population will have, or will have had, a mental illness? The recent surge of interest in psychedelic drugs is due to their potential for more effective tr...
Dave Jackson | May 10, 2021 |

Psychedelic Leader to Advance Mental Health in 2021 with Growth of Clinics, Lab and Partnerships

(Image via Numinus Wellness Inc.) In 2020, Health Canada began allowing select patients to take psilocybin for relief of end-of-life-distress. This was followed by a proposed regulation revision that could allow doctors to prescribe both psilocybin and MDMA for t...
Stockhouse Editorial | January 14, 2021 |

Novamind Selected by Merck to Advance Research for Treatment-Resistant Depression

Novamind’s subsidiary, Cedar Clinical Research, to serve as a key clinical research site Independent validation of the expertise and capabilities of Novamind in managing clinical trials Adds to established track record conducting research a...
Featured Submission | March 18, 2021 |

A Company on a Mission to Revolutionize Mental Healthcare. Here’s How.

When Stockhouse Editorial last caught up with Cybin Inc. ( NEO.CYBN , NYSE: CYBIN , Forum ) back in October, our audience learned about a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug discover...
Dave Jackson | January 31, 2022 |

Revolutionizing Mental Health Treatment

(Click to play video.) Cybin Inc. ( NEO: CYBN , NYSE: CYBN , Forum ) is a Toronto-based life sciences company initially focused on psychedelic pharmaceutical therapies supporting research to advance psychedelic therapies centered on improving mental health and...
Featured Submission | August 13, 2021 |

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. This morning before U.S. markets opened, clinical-stage biopharmaceutical company Axsom...
Streetwise Reports | December 4, 2019 |

Novamind’s Trial Site for Merck Another Example Of Its Leadership in Mental Health

Novamind’s clinics and clinical research capabilities are already well established to bring alternative mental health therapies, including psychedelic medicine, to market. One of the world’s largest pharmaceutical companies has selected ...
Featured Submission | March 24, 2021 |

Numinus Wellness: The mental health business is estimated to grow to $530 billion by 2030

Numinus Wellness is in the business of psychedelic medicine but, more importantly, the mental health business. The mental health business is a sector that will be worth an estimated $530 billion dollars by the year 2030. Numinus has already seen more than a 618% ...
Brieanna McCutcheon | January 30, 2023 |

Clinical research and tools to address mental health

Our next company is Numinus Wellness Inc. (TSX:NUMI) . Numinus is using the power of psychedelic medicine to make great strides in addressing serious mental health issues. It recently announced its fiscal year 2024 results, which showed strong growth in its busines...
Ryan Dhillon | December 14, 2023 |

XPhyto: Proof of Concept for Mescalin Synthesis

It’s become a much talked-about story on both sides of the Atlantic. XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) (OTCQB: XPHYF) has earned considerable media coverage in recent months due to its expansion into the development of psychedelic d...
Marc Davis | June 9, 2021 |
1 2 3 4 5 6 7 8 9